Glanzmann Thrombasthenia
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
LFBEPTACOG BETA
Hemab TherapeuticsHMB-001
Clinical Trials (2)
Total enrollment: 63 patients across 2 trials
Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)
Start: Oct 2025Est. completion: Dec 20266 patients
Phase 2Recruiting
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
Start: Dec 2022Est. completion: Aug 202757 patients
Phase 1/2Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 63 patients
2 companies competing in this space